From AACR meeting earlier in April/June
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: From AACR meeting earlier in April/June
Well, its great to see early research in other areas. Be great if there were a clinical application in CML BC which basically heralds the end. I am perplexed by the 30mg/kg, 3x/wk dosing which is basically many fold higher than the 9.4 mg/kg q 3 weeks we are seeing used in MF. Am I looking at this right? If true clearly toxicity in human patients would be an issue but maybe the outlook in BC is so dismal, there could be some applicability. bp
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: From AACR meeting earlier in April/June
Looks like the doses in mice have been validated in the early Geron literature:
Utilization of Preclinical Xenograft Data in Predicting Human Imetelstat Target Tissue Concentrations
Utilization of Preclinical Xenograft Data in Predicting Human Imetelstat Target Tissue Concentrations
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm